



Grifols – Withdrawal of Gamunex-C® (immune globulin [human])

- On December 30, 2019, [Grifols announced](#) a voluntary, consumer-level withdrawal of one lot of [Gamunex-C \(immune globulin \[human\]\)](#) injection due to a higher rate of allergic/hypersensitivity type reactions, a small number of which were considered medically significant.
- The withdrawn Gamunex-C was distributed in the U.S. and had a market release date of July 19, 2019.

Product Description	NDC #	Lot # (Expiration Date)
Gamunex-C 10%	13533-800-71	B3GKD00483 (6/12/2022)

- Gamunex-C is indicated for the treatment of primary humoral immunodeficiency in patients 2 years of age and older; idiopathic thrombocytopenic purpura in adults and children; and chronic inflammatory demyelinating polyneuropathy in adults.
- Per Grifols, hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with IVIG products.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to the withdrawn Gamunex-C injection.
- Anyone with an existing inventory of the withdrawn product should stop use and quarantine the product immediately.
- For more information regarding this withdrawal, contact Grifols US Clinical Communications at **1-800-520-2807**.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.